Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€76.00

€76.00

-0.650%
-0.5
-0.650%
-
 
03.11.25 / Tradegate WKN: A14VCK / Name: Glaukos / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Glaukos Corp Stock

The price for the Glaukos Corp stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.650%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Glaukos Corp stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Glaukos Corp in the next few years

Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Glaukos Corp vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Glaukos Corp -0.650% 16.923% 7.042% -37.705% -46.099% 39.450% 62.393%
Bio-Rad Labs Inc. A 0.410% -6.308% 5.134% -20.453% -13.945% -27.804% -47.515%
Neogen Corp. -0.910% 2.804% 10.887% -58.015% -54.167% - -
Haemonetics Corp. 0.470% -1.395% 1.435% -34.769% -43.841% -47.654% -50.698%

News

Why Glaukos Stock Zoomed Almost 14% Higher on Thursday: https://g.foolcdn.com/editorial/images/840542/person-undergoing-an-eye-exam.jpg
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday

Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by

Glaukos (GKOS) Q2 Revenue Jumps 30%
Glaukos (GKOS) Q2 Revenue Jumps 30%

Glaukos (NYSE:GKOS), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of